151 related articles for article (PubMed ID: 33441995)
1. A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis.
Liu YT; Ding HH; Lin ZM; Wang Q; Chen L; Liu SS; Yang XQ; Zhu FH; Huang YT; Cao SQ; Yang FM; Song ZL; Ding J; Geng MY; Xie H; Zhang A; He SJ; Zuo JP
Acta Pharmacol Sin; 2021 Oct; 42(10):1653-1664. PubMed ID: 33441995
[TBL] [Abstract][Full Text] [Related]
2. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB
Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
4. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
5. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss.
Shinohara M; Chang BY; Buggy JJ; Nagai Y; Kodama T; Asahara H; Takayanagi H
Bone; 2014 Mar; 60():8-15. PubMed ID: 24316417
[TBL] [Abstract][Full Text] [Related]
6. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
[TBL] [Abstract][Full Text] [Related]
7. An IgD-Fc-Ig fusion protein restrains the activation of T and B cells by inhibiting IgD-IgDR-Lck signaling in rheumatoid arthritis.
Hu XX; Zhang AJ; Pan WW; Xin QL; Chen JY; Zhang LL; Chang Y; Wu YJ; Wei W
Acta Pharmacol Sin; 2022 Feb; 43(2):387-400. PubMed ID: 33864023
[TBL] [Abstract][Full Text] [Related]
8. Fengshi Qutong capsule ameliorates bone destruction of experimental rheumatoid arthritis by inhibiting osteoclastogenesis.
Li Y; Yang C; Jia K; Wang J; Wang J; Ming R; Xu T; Su X; Jing Y; Miao Y; Liu C; Lin N
J Ethnopharmacol; 2022 Jan; 282():114602. PubMed ID: 34492323
[TBL] [Abstract][Full Text] [Related]
9. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Konda VR; Desai A; Darland G; Bland JS; Tripp ML
Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
Gillooly KM; Pulicicchio C; Pattoli MA; Cheng L; Skala S; Heimrich EM; McIntyre KW; Taylor TL; Kukral DW; Dudhgaonkar S; Nagar J; Banas D; Watterson SH; Tino JA; Fura A; Burke JR
PLoS One; 2017; 12(7):e0181782. PubMed ID: 28742141
[TBL] [Abstract][Full Text] [Related]
12. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.
Paniagua RT; Chang A; Mariano MM; Stein EA; Wang Q; Lindstrom TM; Sharpe O; Roscow C; Ho PP; Lee DM; Robinson WH
Arthritis Res Ther; 2010; 12(1):R32. PubMed ID: 20181277
[TBL] [Abstract][Full Text] [Related]
13. The roles of synovial hyperplasia, angiogenesis and osteoclastogenesis in the protective effect of apigenin on collagen-induced arthritis.
Li Y; Yang B; Bai JY; Xia S; Mao M; Li X; Li N; Chen L
Int Immunopharmacol; 2019 Aug; 73():362-369. PubMed ID: 31132731
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Whang JA; Chang BY
Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
[TBL] [Abstract][Full Text] [Related]
15. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
[TBL] [Abstract][Full Text] [Related]
16. Boldine isolated from Litsea cubeba inhibits bone resorption by suppressing the osteoclast differentiation in collagen-induced arthritis.
Zhao H; Xu H; Qiao S; Lu C; Wang G; Liu M; Guo B; Tan Y; Ju D; Xiao C
Int Immunopharmacol; 2017 Oct; 51():114-123. PubMed ID: 28826044
[TBL] [Abstract][Full Text] [Related]
17. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection.
Byun JY; Koh YT; Jang SY; Witcher JW; Chan JR; Pustilnik A; Daniels MJ; Kim YH; Suh KH; Linnik MD; Lee YM
Sci Rep; 2021 Sep; 11(1):18671. PubMed ID: 34548595
[TBL] [Abstract][Full Text] [Related]
18. Asperosaponin VI protects against bone destructions in collagen induced arthritis by inhibiting osteoclastogenesis.
Liu K; Liu Y; Xu Y; Nandakumar KS; Tan H; He C; Dang W; Lin J; Zhou C
Phytomedicine; 2019 Oct; 63():153006. PubMed ID: 31299594
[TBL] [Abstract][Full Text] [Related]
19. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
Di Paolo JA; Huang T; Balazs M; Barbosa J; Barck KH; Bravo BJ; Carano RA; Darrow J; Davies DR; DeForge LE; Diehl L; Ferrando R; Gallion SL; Giannetti AM; Gribling P; Hurez V; Hymowitz SG; Jones R; Kropf JE; Lee WP; Maciejewski PM; Mitchell SA; Rong H; Staker BL; Whitney JA; Yeh S; Young WB; Yu C; Zhang J; Reif K; Currie KS
Nat Chem Biol; 2011 Jan; 7(1):41-50. PubMed ID: 21113169
[TBL] [Abstract][Full Text] [Related]
20. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
